Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On November 4, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported presentations at the upcoming the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics taking place November 18-20, 2026, in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the presentations, copies will be available on the Acrivon website under "Posters and Presentations" or by using this LINK.

Presentations Details

Late-Breaking Mini-Oral Presentation

Title: Safety, dose optimization, and preliminary antitumor activity from a Phase 1 dose escalation study of ACR-2316, a novel WEE1/PKMYT1 inhibitor
Presenter:
Timothy A. Yap, MBBS, Ph.D., FRCP, The University of Texas MD Anderson Cancer Center
Date and Time: Friday, November 20, 2026; 4:12 p.m. CET
Session: Plenary Session 7 Proffered Papers: Novel Agents and Targets
Abstract Number: 11LBA

Poster Presentations

Title: Acrivon Predictive Precision Proteomics (AP3)-phosphoproteomics uncovers differential mechanisms driving superior activity of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor over clinical-stage WRN helicase inhibitors
Date and Time: Thursday, November 19, 2026; 9:00 a.m. – 5:30 p.m. CET
Session: DNA Repair Modulation
Abstract Number: 162
Poster Number: PB-057

Title: Rapid discovery of selective oral CDK11 inhibitors inducing complete tumor regression in acute myeloid leukemia models using Acrivon Predictive Precision Proteomics (AP3) drug discovery platform
Date and Time: Friday, November 20, 2026; 9:00 a.m. – 3:00 p.m. CET
Session: New Drugs
Abstract Number: 329
Poster Number: PB-121

(Press release, Acrivon Therapeutics, NOV 4, 2026, View Source [SID1234674251])